Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for Induction and Maintenance of Remission in Moderately to Severely Active Ulcerative Colitis
2006-002782-40Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Adalimumab with Placebo (2 arms). Primary endpoints: Clinical remission at Week 8 and Clinical remission at Week 52. Started Jan 2007; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-002782-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002782-40.